Zoetis Inc. $ZTS Holdings Trimmed by Davis R M Inc.

Davis R M Inc. cut its holdings in Zoetis Inc. (NYSE:ZTS) by 9.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 114,700 shares of the company’s stock after selling 12,353 shares during the quarter. Davis R M Inc.’s holdings in Zoetis were worth $17,888,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Nova Wealth Management Inc. acquired a new stake in Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC bought a new position in shares of Zoetis in the first quarter valued at $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the 1st quarter valued at $29,000. REAP Financial Group LLC boosted its stake in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC grew its holdings in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $120.20 on Monday. The firm has a 50 day simple moving average of $144.21 and a 200 day simple moving average of $152.63. Zoetis Inc. has a 52 week low of $117.26 and a 52 week high of $181.85. The stock has a market cap of $52.97 billion, a P/E ratio of 20.69, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZTS. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Stifel Nicolaus set a $140.00 target price on shares of Zoetis in a research report on Tuesday, November 4th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, UBS Group decreased their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Zoetis has an average rating of “Moderate Buy” and a consensus price target of $191.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.